Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Do your due diligence, with regard to investing and world news. Cross reference and challenge your predispositions.
Unrelated (perhaps): I watched a video showing test operation of the new Acela train. In rural Colorado the Acela is being run on a test track. Round and round she goes. 30,000 miles so far. Testing, observing, recording, reviewing, validating, introducing variations...attempting to discover what the best laid plans might have missed, hoping to reveal (despite revelation resulting in delay), the unanticipated. 30,000 miles. They probably could have read the User’s Manual and bench-testing results in...24-48 hours. Just put it on the mainline and let the market determine whether it can handle that dicey curve carving thru the Bronx.
In other news; why is it taking so long to approve vaccinations?
https://www.jhunewsletter.com/article/2020/11/a-closer-look-at-u-s-deaths-due-to-covid-19
In other news; Man Walks on the Moon.
The quote is derived from the abstract contained within:
https://www.researchgate.net/publication/301268761_Antimicrobial_Peptides_Do_They_Have_a_Future_as_Therapeutics
Done and done.
The quote is highlighted on the Brilacidin page of IP’s website.
1.4million, bingo.
Contingent on approval by the FDA for Emergency Use.
The Food and Drug Administration is considering whether to grant emergency use authorization for this drug, along with a similar product developed by Regeneron. The Lilly deal is contingent on the FDA clearing the medicine for emergency use.
1. cybermich, attilathehunt, Crashco
2. dreamer0
That makes 3 of us. The message sent; (in a nutshell), Why not? The publicity alone is worth the time it takes to send an email.
Read up on viral reproductive methods. Then research MOA. B attacks and destroys the virus before it enters a host’s cells.
Drugs designed to interrupt the virus/host cell protein attachment cycle are ignoring the cell to cell transmission achieved via filopodia.
I may be mistaken about the year. Very possible. Regarding the time of year I am certain. I may have pinned it, in my memory, to 2019 because Leo related the story to shareholders at the meeting in 2020.
The deal collapsed August/September of 2019.
I was in attendance with a handful of, mostly supportive, shareholders and one or two disgruntled. (That the few other pro-IPIX attendees who stayed after and compared notes might verify, I wear my hair nearly shaved.) Leo did state that a large pharmaceutical company was poised to do a deal. A change of CEO accompanied by a decision to reconsider corporate direction and the deal was scuttled. Leo was very disappointed and it was clear to me he felt terrible for the failure of what he described as a good deal.
That’s not a quote folks, but my interpretation of his words and sentiments.
...currently manufacturing B for IV... Human testing anyone?
Well? Are you waiting for an introduction? Please, speak.
I hope both you and your girlfriend fully recover.
Please confirm; Following negative result you subsequently tested positive?
................................................................................................. Consider these a starter set. Try them out. You’ll find they are useful. For instance, one might be used to separate an idea from a new idea. Or, you can apply one at the conclusion of an argument statement. Then, after it has signaled the reader to pause and reflect you can dive deeper and provide, compelling and illuminating supporting claims.
............................................................................................ I’m feeling generous, have some more. They are cheap. You might find that you enjoy using them. I wouldn’t want you to run out before learning how to manifest then with the flick of your pinkie.
,,,,,,,,,,,,,,,,,,,,,,,, ??????? !!!!!
Bonus characters. Use them once you’ve mastered the ...............s provided.
Funny how this stone was thrown on the same day the following story was reported in the land of glass houses. You know, when people begin to accept lies, and even perpetuate lies, because the narrative is to their liking they soon find themselves in a world where truth is indiscernible from lie.
I’m being silly of course. We have lived in the land of elastic truth for years.
Official Counts Understate the U.S. Coronavirus Death Toll - The New York Times
https://www.nytimes.com/2020/04/05/us/coronavirus-deaths-undercount.html
https://www.nytimes.com/2020/04/05/us/coronavirus-deaths-undercount.html?action=click&module=Spotlight&pgtype=Homepage
It’s too soon for a deal resulting from the Covid-19 testing cycle. My reply relates to pre-pandemic business.
That said, I do worry that the free testing may have a chilling effect on deal making.
Putting myself in the, expensive, shoes of a Big Pharma CEO I can imagine the following logic. “Why do a deal, the value of which is predicated on possible efficacy, now? Why buy the risk? The Government is paying for the testing we would have to do post-deal. The Government will de-risk Innovation Pharmaceuticals for us.”
Sometimes the wise CEO is a man of inaction. “Don’t just do something, sit there.”
Innovation Pharmaceuticals is holding out for a financial agreement that values B accurately. “We know what we have.” IP will not settle for a low ball offer. Leo hasn’t blinked. Will big Pharma blink first?
I’m extremely skeptical also. I think it’s a USAToday error.
Intriguing.
Not a very active pharma company. GeneOne hasn’t added an update to their timeline since 2016.
There is a common thread between GeneOne and Inovio. David B. Weiner is on the Scientific advisory board for both GeneOne and Inovio.
Random breadcrumb or one in a trail worth following? USAToday may be inadvertently breaking IPIX news but could just as easily be misreporting. They may have mistaken Inovio for Innovation Pharmaceuticals.
Funny, because etrade couldn’t process my buy (above the ask).
First, check your shoe.
Second, goodby.
Come out of the doorway baby, you’ll catch your death in the cold. Smell the science. That’s the only thing that matters here.
GLTA (true) Longs.
You have been here all of 19 minutes. Great to get your seasoned, time worn, opinion.
Welcome newbies!
Look at Bigge’s post history.
Was there an intended irony, illustrated by the contradiction between the bravado of paragraph 3 and the observed reality of paragraph 4?
Best investigative indication reveals 1,900 Americans had been tested as of Thursday. (South Korea, with a head start, has tested 66,000 and is testing 10,000/ week.) We have yet to define the extant of our challenge. Government efforts are being made, State and Federal, and in a far more proactive manner private sector, corporate, policy action is being taken. Still the word supreme has no place in a description of the US response. But, if we don’t get our shit in order soon I’ll grant the use of supreme to define the level of shit storm we’ll experience.
We have got to do better. Quickly.
Keep testing new epitaphs. IPIX will keep testing new indications.
When your opponents have run out of legitimate argument and turn to Ad homonyms, victory is near.
GLTA (true) Longs. IPIX will succeed if the science proves out. Leo has out maneuvered those who would profit at the expense of millions in medical need. It’s down to clinical results.
Early and Mid-stage study results point toward B efficacy in multiple indications. We’re on the verge of final validation. Results, not blather, will write the IPIX story. (Additional studies funded by Gov’t playing catch-up are bonus.)
20/20, 2020!
Sure. IF Dusquetide makes it to market AND IF it is higher efficacy than the other two drugs, THEN when it is available a few years from now patients will flock to it.
Lots of value available for all three companies to capture. You may even see combo treatments. Lots of IFs and time before Dusquetide is an option for patients.
Nothing is written.
Scotland.
Despicable.
You could have just said; "Read my post history."
You spent 30 minutes writing the same nonsense you’ve been spewing for years.
All,
Do your own DD. Just around the corner? Yes, I believe IPIX breakout is just around the corner. Spend a few days reading up on IPIX. But don’t wait too long to invest.
GLTA True Longs
Correct. Your telling is more crafted then mine. Thank you.
No, I lost hope NKTR would ever break out and I sold at a profit.
For 16 years NKTR sp languished, traded roughly flat. I bought at 12 (2014) and sold at 23 (2017) after losing patience (and hope). Now at 82.
NKTR suffered slings and arrows. I surrendered. A small profit was made, my investment was small.
IPIX’s day is coming. I will not lose patience. I will not surrender. (Given the current intelligence and public results.)
BioPharm takes time. I began accumulating CTIX within months of investing in NKTR. My investment is large. So too will be the pay off.
GLTA true Longs.
Sorry TheDane.
I was gently teasing you earlier for misunderstanding the thread as claims of 5% IPIX ownership. I teased with the name Roseanne Roseannadanna. But I was wrong. It was Gilda Radner’s classic Emily Litella who, realizing her error, ended each misguided rant with, "Never mind."
(I should be working, not posting.)
Oh well, it did lead me down memory lane and a YouTube review of the great Gilda Radner comedy.
Good luck Longs!
Roseanne Roseannadanna
Wait for it...